915404-94-3
915404-94-3
Chemical Structure
Carlumab
Synonym(s): CNTO 888
- No. CAS: 915404-94-3
- Molecular Weight:(144.87 kDa)
IUPAC Name: tert-butyl (3-fluoro-5-nitrophenyl)carbamate
SMILES: [Carlumab]
Biological Activity: Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) monoclonal antibody. Carlumab binds to human CCL2 and neutralizes its pro-fibrotic activity. Carlumab inhibits tumor growth by reducing macrophage infiltration and decreasing tumor microvessel density. Carlumab can be used in cancer research, such as prostate cancer[1][2].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Carlumab | 97.80% | Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) monoclonal antibody. Carlumab binds to human CCL2 and neutralizes its pro-fibrotic activity. Carlumab inhibits tumor growth by reducing macrophage infiltration and decreasing tumor microvessel density. Carlumab can be used in cancer research, such as prostate cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Raghu G, et al. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur Respir J. 2015;46(6):1740-1750. [Content Brief]
- [2]. Pienta K J, et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer[J]. Investigational new drugs, 2013, 31(3): 760-768.
